U N C O R R E C T E D P R O O F
Bystander gene activation by a locus control region Introduction
Transcriptional controls in higher eukaryotes can be exerted over extended distances (Ptashne, 1986; Bresnick and Tze, 1997) . Remote regulatory elements can function by establishing extensive 'activated' chromatin domains that encompass target promoters (Vyas et al, 1992; Hebbes et al, 1994; Bulger and Groudine, 1999; Elefant et al, 2000; Forsberg and Bresnick, 2001; Ho et al, 2002) . Alternatively, remote regulatory elements can be brought into close juxtaposition with target promoters via long-range 'looping' or 'tracking' mechanisms (Mueller-Storm et al, 1989; Tewari et al, 1996; McDowell and Dean, 1999; Carter et al, 2002; Tolhuis et al, 2002) . Sets of transcriptional regulatory determinants responsible for long-range gene activation pathways are generally referred to as locus control regions (LCRs) (Forrester et al, 1987; Grosveld et al, 1987) . The identification of LCRs in a wide array of gene systems suggests that long-range transcriptional controls constitute common pathways for gene activation in higher eukaryotes. The extensive distances over which long-range controls can be exerted, and the close packing and random arrangement of many loci in the mammalian genome, establishes the potential for mutual interference among neighboring genes with distinct developmental or tissue specificities. Understanding how this significant problem in gene regulation is overcome is of fundamental importance. Insulator and boundary elements have been identified that can block a subset of such unwanted interactions (Chung et al, 1993; Hebbes et al, 1994; Bell and Felsenfeld, 1999) . However, simple linear models of insulator/barrier function would be incompatible with effective insulation between loci with overlapping transcriptional control determinants. This suggests that more complex models of gene 'insulation' need to be formulated. Alternatively, certain loci may in fact not be fully insulated from the influence of unrelated transcriptional determinants and chromatin domains in their local environment. In this case, genes may be expressed in 'inappropriate' tissues or developmental settings. Such lack of precision in gene expression may be tolerated by the cell and/or might be compensated by post-transcriptional regulatory pathways.
The human growth hormone (hGH) cluster contains five genes expressed specifically in the pituitary (hGH-N) or in the placenta (hCS-L, hCS-A, hGH-V, and hCS-B). The hGH LCR in these two tissues is composed of partially overlapping sets of HS. HSI and HSII are specific to pituitary chromatin, HSIV is specific to placental chromatin, while HSIII and HSV are formed in the chromatin of both tissues (Jones et al, 1995) . The mechanism of long-range activation by the hGH LCR has been best defined in the pituitary. The two closely linked pituitary-specific HS, HSI and HSII, are situated 14.5-15.0 kb 5 0 to the hGH-N promoter. These HS appear to recruit HAT activity with subsequent bidirectional spreading of histone acetylation (Elefant et al, 2000; Ho et al, 2002) . These reactions establish a continuous 32 kb domain of acetylated chromatin that extends to encompass the hGH-N promoter. Epigenetic alterations within this domain are required for trans factor binding at the hGH-N promoter and for effective hGH-N transcriptional activation (Ho et al, 2002) . Targeted inactivation of HSI results in loss of the acetylated histone domain in pituitary chromatin and is accompanied by 90-95% loss of hGH-N transgene expression (Ho et al, 2002) . Thus hGH-N transcriptional activation and the establishment of the extensively modified hGH LCR chromatin domain are intimately linked processes and both are dependent on the function of HSI.
U N C O R R E C T E D P R O O F
The human CD79b/Igb gene (referred to throughout as hIgb) functions specifically in B lymphocytes (Hermanson et al, 1988) . Igb proteins form heterodimers with Iga to create the signal transduction subunit of the B-cell receptor (Campbell et al, 1991; Clark et al, 1992) . As such, Igb plays a critical and nonredundant role in B-cell differentiation and function (Papavasiliou et al, 1995) . There are no additional functions defined for this protein. Considering this B-cell specificity, it is interesting and potentially problematic that the hIgb gene is situated between HSI of the hGH LCR and the hGH-N promoter (Bennani-Baïti et al, 1998a, b) . This organization places the hIgb locus within a hyperacetylated hGH LCR chromatin domain in somatotrope nuclei. The close packing of the hGH-N, hIgb, and the hGH LCR thus presents a complex and potentially informative model to study mechanisms by which genes are shielded from each other's transcriptional control elements.
In the present study, we report the unexpected observation that hIgb is actively transcribed in the pituitary. Interestingly, activation of the hIgb locus in the pituitary occurs in the absence of B-cell-specific transcription factors required for hIgb expression in B cells. This activation of hIgb in the pituitary reflects its fortuitous positioning within the activated chromatin domain generated by the hGH LCR. Thus, hIgb is not shielded from the hGH LCR as might be expected, but instead is robustly activated by it. This 'bystander' gene activation may represent a relatively common phenomenon. As such it would have important implications for models of developmental and tissue-specific gene regulation within the mammalian genome.
Results

An hIgb transgene with extensive flanking regions is appropriately expressed in mouse B cells
The five genes within the hGH cluster are activated in either pituitary or placenta. In both situations, this activation is dependent on the action of a set of remote 5 0 hGH LCR elements (Introduction). The B-cell-specific hIgb gene is situated between the hGH LCR and the hGH cluster. We sought to identify a separate set of chromatin determinants in this region that were responsible for activation of hIgb in B cells. Defining such determinants would allow us to model inter-relationships of transcriptional control elements within this tightly packed region of the genome. As an initial step, we assessed the expression of hIgb from the 87 kb hGH/P1 transgene ( Figure 1A ). This previously described transgene (Su et al, 2000) contains hIgb along with extensive flanking sequences. The flanking sequences include 31 kb of 5 0 -flanking sequences encompassing the entire hGH LCR and extending into the striated muscle-specific SCN4A gene and 51 kb of 3 0 -flanking sequences that contain hGH-N and three of the four placentally expressed genes of the hGH gene cluster. The expression of hIgb from the hGH/P1 transgene was compared to that of the endogenous mouse (m) Igb ( Figure 1B) . hIgb was robustly expressed in the spleens of four hGH/P1 transgenic mouse lines. Expression per transgene copy was maintained within a two-fold range, varying from 25 to 42% of endogenous mIgb. Immunofluorescent analysis of transgenic spleens confirmed that hIgb protein expression was restricted to the B-cell compartment ( Figure 1C) . B-cell specificity was further substantiated by flow sorting of splenocytes (data not shown). These results indicated that the hGH/P1 transgene contains determinants sufficient to establish an autonomous, site-of-integration-independent chromatin environment that supports robust expression of hIgb in mouse B cells.
hIgb transgene is expressed in the mouse pituitary
The fidelity of hIgb expression from the hGH/P1 transgene was evaluated by a tissue survey ( Figure 2A ). As expected, the spleen contained high levels of hIgb and mIgb mRNAs. In contrast, these mRNAs were at or below trace levels in the brain, heart, kidney, and liver, and at a slightly higher level in the intestine. Surprisingly, a strong hIgb mRNA signal was detected in the pituitary. While an exact quantitative comparison of hIgb mRNA levels in B cells and somatotropes is complicated by the presence of mixed cell populations in the spleen and pituitary, it was clear that the hIgb mRNA level in the pituitary was robust, approximating that in the spleen.
Analysis of all four hGH/P1 transgenic lines confirmed the robust expression of hIgb mRNA in the pituitary. These studies further revealed that the pituitary expression was copy number dependent, varying by less than three-fold ( Figure 2B and real-time RT/PCR analysis, data not shown). Consistent with the expression of the hIgb transgene in the pituitary, we also detected the endogenous mIgb mRNA in this tissue, although at significantly lower levels.
To address the possibility that hIgb mRNA in transgenic mouse pituitary might reflect B-cell contamination, we assayed for mIga mRNA (Figure 2A ). Igb and Iga are encoded on separate chromosomes in both human and mouse genomes (Campbell et al, 1991; Clark et al, 1992) . As expected, mIga mRNA was easily detected in transgenic mouse splenic RNA. However, mIga mRNA was absent in the pituitary RNA samples, and could not be detected in any of the other surveyed transgenic tissues ( Figure 2A ). We concluded that the hIgb gene is robustly transcribed in the transgenic mouse pituitary.
The overall structure of hIgb mRNA in transgenic pituitary and B cells is very similar The structure of the hIgb transcripts in the pituitary was assessed. We considered two possible origins for the pituitary hIgb transcripts that would differentiate them from authentic (B cell) Igb mRNAs. First, these transcripts could represent noncoding (intergenic) RNAs randomly generated from the active hGH LCR chromatin domain. Intergenic transcription has been described throughout the human b-globin LCR (Ashe et al, 1997; Routledge and Proudfoot, 2002) and it has been implicated in chromatin modification (Gribnau et al, 2000) . Second, hIgb may be transcribed in the pituitary from an alternative promoter distinct from that used in B cells. To address these possibilities, hIgb mRNA size was analyzed by Northern blotting. These data revealed that hIgb mRNA in transgenic mouse pituitaries was of the same size as in transgenic mouse purified lymphocytes and human B cells ( Figure 3A) . The normal size of the pituitary hIgb mRNA was incompatible with random transcription within the LCR domain.
To determine whether the pituitary and B-cell hIgb mRNAs begin at different promoters, the structures of their respective 5 0 termini were determined by 5 0 rapid amplification of cDNA ends (5 0 RACE). hIgb mRNAs isolated from the hGH/P1 transgenic pituitary and human B-cell line revealed multiple termini is consistent with a previous study (Thompson et al, 1996) and with the TATA-less/GC-rich structure of the hIgb promoter (Geng and Johnson, 1993; Donohoe and Blomberg, 1997; Dong et al, 2000) . Of particular note, the 5 0 -terminal sequences in the 14 randomly selected pituitary hIgb cDNAs were continuous with the genomic sequence encompassing exon 1 of the hIgb gene. These data argued against the initiation of transcription from an alternative promoter/ exon. The 5 0 -RACE sequence data also showed that pituitary hIgb is normally spliced across intron 1. The correct size of the hIgb RT-PCR product extending between exons 5 and 6 (see Figure 1B) Splenic expression of hIgb from the hGH/P1 transgene is copy number dependent. hIgb mRNA and endogenous mIgb mRNA were coamplified (RT/PCR) and the cDNAs were distinguished by restriction analysis. A representative RT/PCR analysis is presented in the autoradiograph and a diagram of the assay is shown below. The 5 0 primer was 32 P-end labeled and the PCR products were digested with HinfI (H) that exclusively digests the mIgb PCR product and ScfI (S) that exclusively digests the hIgb PCR product. The 5 0 -labeled fragments generated from mouse (63 bp) and human Igb (95 bp) cDNAs are indicated (arrowheads). These signals were quantified from four unique four hGH/P1 transgenic lines. The transgene copy number for each line is noted below each lane. Transgene expression per transgene copy was normalized to endogenous mIgb and values are indicated as percentages below each respective lane. (C) hIgb transgene is selectively expressed in the white pulp of the mouse spleen. (Left) Hematoxylin and eosin staining of an hGH/P1 transgenic spleen showing normal architecture of the spleen and indicating the defined areas of red pulp (rp) and white pulp (wp). (Middle) hGH/P1 transgenic spleen stained with anti-hIgb (Texas red). The intense hIgb staining is restricted to white pulp (wp) consistent with the local abundance of B lymphocytes. (Right) Nontransgenic, wild-type (WT) spleen stained with anti-hIgb. The absence of a signal confirms the species specificity of the anti-hIgb antibody.
correctly spliced across intron 5. Thus, on the basis of a number of structural parameters, we concluded that the hIgb mRNA in the pituitary is closely related, if not identical to the mature, authentic B-cell hIgb mRNA.
Igb mRNA is expressed in the human pituitary
We next considered whether the unexpected expression of hIgb mRNA in the mouse pituitary reflected a peculiarity of the transgenic model. PolyA-primed cDNA was generated from normal human pituitary and from two human pituitary somatotrope adenomas ( Figure 4 ). Controls for this study included mRNA samples from a transgenic pituitary, from human peripheral blood leukocytes (PBLs), and from a human erythroid cell line (K562). The identity of the pituitary samples was confirmed by the presence of hGH mRNA. hIgb mRNA was detected in all three human pituitary samples in the absence of hIga mRNA. In contrast, the control PBLs contained both hIgb and hIga mRNAs but neither was detected in K562 cells. The relative levels of hIgb mRNA and hGH mRNA were similar in a comparison of the normal pituitary and pituitary adenoma #361. This comparison, however, revealed a relatively higher level of hGH mRNA in adenoma #373. This variation between the two adenomas may reflect the enrichment for somatotropes within the surgical samples or be a peculiarity of the adenoma pathology. This was not further explored. From these data we concluded that the transcription of hIgb from the hGH/P1 transgene in the mouse pituitary faithfully recapitulated the expression of hIgb in primary human pituitary tissues. Figure 1B with the exception that the 3 0 primer is 32 P-end labeled. The figure shows the PCR products digested with ScfI; the larger band (336 bp) corresponds to mIgb and the smaller (250 bp) to hIgb (labeled arrows). A separate RT/PCR of mIga mRNA was carried out to monitor B-lymphocyte contamination in each tissue. The levels of hIgb, mIgb, and mIga are shown relative to a b-actin mRNA loading control (ethidium bromide-stained gel). (B) Pituitary expression of hIgb mRNA from the hGH/P1 transgene was copy number dependent. Pituitaries from four hGH/P1 transgenic mouse lines were assayed by RT/PCR for hIgb mRNA. The level of hIgb mRNA was normalized to endogenous mouse pituitary Igb mRNA and this value is shown as a percentage below each pair of lanes after correction for gene copy number. 
5′-RACE analysis
Wall, 1993; Thompson et al, 1996; Akerblad et al, 1999) . Therefore, the expression of hIgb in the pituitary is likely to reflect an alternative pathway of gene activation. We speculated that this alternative mode of activation might reflect the localization of the hIgb gene within the chromatin domain established in the pituitary by the hGH LCR. HSI of the hGH LCR has a unique and necessary role in establishing this activated chromatin domain (Introduction). We generated a series of transgenic lines carrying the hIgb gene flanked by native sequences that either included (À8.0Igb transgene) or excluded HSI (À1.3Igb transgene and À0.2Igb transgene) ( Figure 5A ). A semiquantitative co-RT/PCR assay was used to assess hIgb mRNA levels in the pituitaries from mice representing three or more independent lines carrying each of the three hIgb transgenes. hIgb mRNA was robustly expressed from the transgenes containing HSI (À8.0Igb). In contrast, hIgb mRNA expression was dramatically lower in mice carrying transgenes truncated 3 0 to HSI (À1.3Igb and À0.2Igb) (Figure 5B, left) . hIgb mRNA levels in representative lines were separately assessed by real-time PCR and normalized to endogenous mouse GAPDH mRNA (data not shown, see Materials and methods). The two sets of mRNA assays were in full agreement. These data support the central role of HSI in activating hIgb transcription in the pituitary.
The involvement of HSI in the activation of hIgb in the pituitary was further tested by a second approach. Deletion of a core 99 bp segment of HSI (hGH/P1DHSI transgene; see Figure 5A ) destroys HSI formation, dramatically decreases acetylation throughout the hGH LCR, and results in a 20-to 40-fold decrease in hGH-N transgene expression (Ho et al, 2002) . The impact of HSI on hIgb transcription was tested by comparing levels of hIgb mRNA in the pituitaries of lines carrying the intact hGH/P1 transgene to lines carrying the inactivated HSI (hGH/P1DHSI). This comparison revealed a mean 47-fold decrease in hIgb mRNA in the lines lacking a functional HSI (Figure 5B, right) . The data were confirmed by independent real-time PCR analysis of hIgb mRNAs in representative lines (data not shown). Thus, the activation of pituitary hIgb transcription was dependent on HSI, the major hGH LCR determinant in the pituitary.
Expression of hIgb in B cells is independent of hGH LCR action
The formation of HSI of the hGH LCR is specific to the pituitary (Jones et al, 1995) and hGH-N mRNA is not found in the spleen ( Figure 6A ). Despite this tissue specificity of hGH LCR function, the pronounced effect of HSI on hIgb expression in the pituitary prompted us to formally test whether HSI enhances hIgb expression in B cells. Comparison of hIgb mRNA levels in the spleens of hGH/P1 and hGH/P1(DHSI) mice revealed equally robust and copy number-dependent levels from both transgenes ( Figure 6B ; 0 from the hIgb gene promoter. Note that hGH/ P1 and À8.0Igb transgenes include HSI whereas this determinant is excluded from the À0.2Igb and À1.3Igb transgenes. In hGH/ P1(DHSI), a 99 bp segment (dashed box), corresponding to the critical core elements of HSI, has been deleted from the hGH/P1 transgene (Ho 2002) . (B) HSI of the hGH LCR is a critical determinant of pituitary hIgb expression. The ratios of pituitary hIgb to mIgb mRNAs in the series of hIgb transgenic mouse lines (A) are shown. Mice from F1 or later generations and from at least three independent lines (dots) were analyzed (X-axis). The hIgb to mIgb mRNA ratios in each transgenic pituitary were plotted on the Y-axis as a percentage. The horizontal lines represent the mean values for each construct in the three or more lines analyzed. Representative co-RT/PCR endonuclease cleavage assays corresponding to each construct are shown below the graph. Wild-type mouse (WT) pituitary RNA was used as negative control. Expression ratios were corrected for transgene copy number.
compare with Figure 1B ). These data are consistent with the tissue specificity of hGH LCR function and support the conclusion that HSI activates hIgb transcription in the pituitary but has no appreciable function in the B-cell chromatin context.
hIgb is not activated by the hGH LCR in the placenta
The hGH LCR activates expression of pituitary and placental genes from the hGH cluster via distinct epigenetic pathways. In the pituitary, the LCR establishes a continuous 32 kb domain of acetylated chromatin (Elefant et al, 2000; Ho et al, 2002) . In contrast, acetylation of the LCR and the GH genes in placental chromatin is highly localized to two discontinuous regions, HSV-HSIII region and the region encompassing the four closely linked placental genes within the cluster (Kimura et al, 2004) . Of particular note, levels of histone H3 and H4 acetylation in the region encompassing hIgb (between HSIII and the hGH gene cluster) are quite low in placental chromatin when compared to the pituitary. The dependence of hIgb gene activation in the pituitary on its positioning within a highly acetylated chromatin domain could therefore be further addressed by analyzing hIgb expression in the placenta. In comparison to the robust expression of hIgb mRNA in the transgenic pituitary and human B cells, hIgb mRNA in the placental samples could only be detected at trace levels ( Figure 6C and data not shown). These data support the conclusion that activation of hIgb is directly related to its location within the highly acetylated LCR chromatin domain formed in the pituitary.
hIgb mRNA in the pituitary is not effectively expressed at the protein level
The presence of hIgb mRNA in the pituitary suggested that hIgb protein might be synthesized at this site. hIgb protein could theoretically contribute to a novel somatotrope signaling complex. hIgb protein expression was therefore assessed by Western analysis of transgenic pituitary extracts. A strong hIgb signal was detected in the transgenic spleen extracts and human B-cell extracts. In contrast, the Western blots failed to reveal convincing evidence for hIgb in the pituitary (Figure 7 ). Immunofluorescent microscopy was carried out using hGH/ P1 transgenic pituitaries. These studies were essentially negative with only a rare cell showing evidence of positive hIgb staining (data not shown). We concluded that the abundant hIgb mRNA in the pituitary is either poorly translated or hIgb protein, once synthesized, is rapidly catabolized due to the lack of a partnering Iga.
Discussion
Regulation of eukaryotic gene transcription reflects complex interactions among transcription factors, cofactor complexes, and epigenetically modified chromatin structures. The present study revealed that the activated chromatin environment established in pituitary somatotropes by the hGH LCR triggers This ectopic activation of hIgb reflects its fortuitous positioning within the hGH LCR chromatin domain. Activation of the 'bystander' hIgb gene by the hGH LCR occurs in the absence of B-cell-specific trans factors. The cis-acting selectivity of this effect is underscored by the observation that Iga, the Bcell-specific partner of Igb, remains unexpressed in the mouse and human pituitaries. Thus, hIgb can be activated in two tissues by two distinct mechanisms: it can be driven in the spleen by a pathway controlled by B-cell-specific transcription factors and it can be driven in the pituitary by the epigenetic influence of an encompassing somatotrope-specific chromatin domain. The latter 'bystander' gene activation pathway, which is unlikely to be unique, adds to the complexity of gene regulation and tissue specification models. The mechanistic basis for hIgb expression in pituitary was initially explored by defining the structure of the hIgb transcripts. Northern blot analysis, RT/PCR across splice junctions, and 5 0 RACE indicated that pituitary hIgb transcripts corresponded to full-length, polyadenylated hIgb mRNAs ( Figures 1B, 3A and B) . 5 0 -RACE analysis further revealed a heterogeneity of the 5 0 ends of hIgb in both B cells and pituitary that is consistent with the lack of a TATA motif and the GC-rich structure of the hIgb promoter (Geng and Johnson, 1993; Donohoe and Blomberg, 1997; Dong et al, 2000) . Thus, the hIgb gene, although considered B-cell specific, appears to be robustly expressed as a normally structured mRNA in the pituitary.
Although the structures of the Igb mRNAs in B cells and in the pituitary are remarkably similar, subtle differences were noted. Northern analyses ( Figure 3A and data not shown) revealed a more sharply focused Igb mRNA band in B cells than in the pituitary and the 5 0 -RACE analysis revealed that the 5 0 termini of the Igb mRNA in B cells were more tightly grouped than in the pituitary. These observations may reflect qualitative differences in the accuracy of transcriptional initiation in B cells and by the 'bystander' pathway of Igb activation in the pituitary.
It is of note that endogenous mIgb mRNA is also detected in mouse pituitaries. However its levels, when corrected for gene copy number, are substantially lower than hIgbmRNA expression from the hGH/P1 transgene (Figure 2A and B) . This could reflect a difference in the chromatin environment and transcriptional control of the human and murine GH loci. Whereas primates have a five-gene GH cluster, rodents have a single, isolated GH gene (Barsh et al, 1983; Chen et al, 1989) . Whether the single mGH gene is under LCR control has not been determined. Computer searches reveal a conserved noncoding region in the mouse genome 5 0 to the mIgb gene that can be aligned with HSI of the hGH LCR. However, it is not known if this sequence represents a functional correlate of the hGH LCR. A definitive comparison should emerge once detailed epigenetic and functional analyses of the mGH locus are established.
The 'bystander' effect exerted by the hGH LCR on hIgb in the pituitary raised the question of whether hIgb exerts a reciprocal activation of hGH in B lymphocytes. Analysis of hGH/P1 transgenic mice failed to reveal hGH-N mRNA in spleen and analysis of human B cells was similarly negative for hGH-N mRNA ( Figure 6A ). These results suggest that the hIgb gene is activated by localized chromatin modifications that do not extend downstream to encompass the hGH-N promoter. This model can now be tested by defining the epigenetic modifications linked to hIgb expression in B cells.
The observation that genes with distinct expression patterns can be located in close proximity has led to the concept that these genes must be functionally shielded from one another (Dillon and Sabbattini, 2000) . Such shielding may be mediated by boundary or insulator elements that protect adjacent genes from mutual positive or negative interference. This model has been most actively supported in studies of the chicken (c) b-globin locus (Chung et al, 1993 (Chung et al, , 1997 Hebbes et al, 1994) . A constitutive HS located at the 5 0 border of the hyperacetylated cb-globin cluster defines the active domain and separates it from an adjacent heterchromatic region (Prioleau et al, 1999) . Although such boundaries may be present in certain genomic regions, their function(s) have yet to be extensively tested in their native contexts. The present finding suggests that this model is not universal and that gene expression in higher eukaryotes may not be so neatly controlled in all cases.
Activation of the hIgb gene in the pituitary may be difficult to explain solely on the basis of its presence within an active chromatin domain. For example, the ha-globin genes are situated within a region of constitutively open chromatin and yet their expression is erythroid specific (Vyas et al, 1992) . Therefore, an open chromatin environment does not guarantee transcription activation. While the activated chromatin context is an essential prerequisite for activation, transcription factor association is certainly involved in this process. There are interesting relationships between B lymphocyte and somatotrope transcription factors that may be relevant to hIgb activation in the pituitary. Motifs involved in Igb expression bind factors such as early B-cell factor (EBF), Oct-2, LyF1/mB, and PU.1 (Omori and Wall, 1993; Thompson et al, 1996; Akerblad et al, 1999) . The octamer motif, bound by Oct-2 and the ubiquitous Oct-1, is a major determinant of Igb promoter activity. Oct-1, Oct-2, and Pit-1 belong to the family of POU homeodomain transcription factors. Pit-1 is abundantly expressed in pituitary cells (Ingraham et al, 1988 ; Asa et al, 1993) and is critical to hGH-N activation (Shewchuk et al, 1999 (Shewchuk et al, , 2002 . Crossbinding of Pit-1 and the Oct factors to corresponding cis elements has been demonstrated in vitro, although it has not been possible to confirm actual crossactivation using cell transfection models (Elsholtz et al, 1990) . It is possible that the hIgb promoter, when in the activated hGH LCR chromatin domain, is permissive to binding by abundant and closely related factors such as Pit-1. Alternatively, the active chromatin conformation within the hGH LCR may promote direct association of the basal transcriptional complex. This later scenario might predict a slightly less constrained site of transcription initiation of hIgb in the pituitary relative to B cells. 'Bystander' activation of hIgb, while secondary to the effects of the hGH LCR, may have a subsequent impact on hGH expression itself. Studies in the b-globin locus have demonstrated that two genes, when under the control of a common LCR, can alter each other's expression via transcriptional competition (Giglioni et al, 1984; Dillon et al, 1997) . Prior studies of the hGH cluster revealed that direct linkage of HSI,II to the hGH-N transgene results in overexpression of serum hGH and a giant phenotype in transgenic mice (Jones et al, 1995) . This superinduction of hGH could reflect the artificial proximity of HSI,II to the hGH promoter in the transgene construct, or alternatively, it might reflect the exclusion of a competing hIgb transcriptional unit. Weighing against this second possibility is the observation that mice homozygous for deletion of the mIgb gene promoter lack evidence of growth abnormalities (Gong and Nussenzweig, 1996; Nussensweig, personal communication) . Thus transcriptional inactivation of Igb, at least in the mouse, fails to significantly impact on mGH expression. Whether bystander activation of a gene can have a secondary impact on its local environment can now be explored in greater detail.
The present data suggest that genes and their cis-acting sequences are not necessarily organized into discrete and functionally insulated chromosomal domains. The prevalence of long-range transcriptional controls in higher eukaryotes and the presence of extensive domains of modified chromatin make it likely that transcriptional interactions among closely packed genes may be the rule rather than the exception. Such 'bystander' effects impact on current concepts regarding tissue specificity, developmental controls, and widen the considerations of how gene control circuits are organized. Together, these observations add another layer of complexity to our understanding of gene activation mechanisms.
Materials and methods
Cell lines and primary cells
Human K562 erythroid cell line and human lymphoblastoid cell line CRL-1484 were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin. Peripheral blood lymphocytes (PBLs) from a normal donor were purified from fresh, heparinized whole-blood samples on Ficoll-Paque gradients (Amersham Biosciences). Studies of human samples were approved by the University of Pennsylvania Institutional Review Board.
Human pituitary and placenta samples
A preparation of polyA-primed cDNA from normal human pituitaries was a gift of Dr Roman Perez-Fernandez (Compostela University). Pituitary GH-secreting adenomas were donated by Dr Peter J Snyder (University of Pennsylvania). Portions of human fullterm placentas were obtained from the Obstetrics service at the University of Pennsylvania.
RT/PCR analyses
In all cases, 0.5 mg of total RNA extracted from tissues or cell lines was reverse transcribed with an oligo-dT primer in the presence of AMV reverse transcriptase, then coamplified using a primer set corresponding to regions conserved between human and mouse (Table I) . Either the 5 0 or 3 0 primer was end-labeled with [g-32 P]ATP by T4 polynucleotide kinase. This primer set spans intron 5 in order to distinguish cDNA from amplified genomic DNA by fragment sizes. PCR products were digested with a restriction enzyme; mIgb cDNA is specifically cleaved by HinfI, hIgb cDNA by SfcI, and hGH-N by BstNI. Fragments were separated on 6% polyacrylamide/ denaturing gels, and bands were quantified on a Storm 840 PhosphorImager (Molecular Dynamics, Sunnyvale, CA). The ratios of digested cDNA fragments were normalized to transgene copy number. b-actin and GAPDH cDNAs were amplified for 24 cycles with unlabeled primers and analyzed on agarose gels. All PCR results were determined to be within the linear range of amplification by analysis of serial cycles.
RNA quantification by real-time RT/PCR
Pituitary RNA samples were reverse transcribed with random hexamers in the presence of MMLV reverse transcriptase. The cDNA was diluted to 10 ng/ml and was used for real-time PCR using TaqMan reagents on an ABI Prism 7700 Sequence Detector (Applied Biosystems). All samples were run in duplicate. Amplification of the hIgb mRNA was normalized with a reference mGAPDH mRNA probe. All primers and probes for real-time analysis of hIgb and mGAPDH mRNAs were standardized reagents purchased from Applied Biosystems.
Northern analyses
Total RNA was extracted from lymphocytes (spleen), pituitaries, and cell lines with RNA-Bee (Tel-Test, TX). A 20 mg portion of each RNA sample was separated on a 1.2% agarose gel containing 2.2 M formaldehyde in 1 Â MOPS, and transferred to a Zeta-Probe membrane (Bio-Rad). The membrane was probed with 32 P-labeled hIgb cDNA probe (Table I ; Northern probe) at 651C in PerfectHyb buffer (SigmaAldrich). The membrane was then washed (1 Â SSC, 0.1% SDS, 0.5 Â SSC, 0.1% SDS, and finally 0.1 Â SSC, 0.1% SDS) at room temperature to 651C and signals were detected by exposure to a phosphorimager screen.
5
0 rapid amplification of cDNA ends mRNAs isolated from B-cell line 1484 and hGH/P1 transgenic pituitaries were reverse transcribed using an antisense hIgb-specific primer corresponding to a site in exon 6 of hIgb (5 0 TCATGGGGCGACCTGGCTC3 0 ). The RT product was ethanol precipitated in the presence of carrier (glycoblue) and resuspended in water. A polyA tail was added to the 3 0 end of the transcribed cDNA using terminal dinucleotidyl transferase (Promega). An initial PCR was run using the oligo-dT-adaptor primer (Table I) and an hIgb-specific antisense primer on exon 3 (Table I) . A subsequent nested PCR was run using the same oligo-dT-adaptor primer and hIgb-specific antisense primer corresponding to a region of exon 2 (Table I ). The products were cloned into the pGEMT vector system I (Promega) and sequenced by chain termination.
FACS analysis of mouse spleen B cells for hIgb protein
Spleen cells were harvested, suspended in PBS, and lymphocytes were isolated on Ficoll gradients. Cells were stained for 30 min using a panel of monoclonal antibodies conjugated to fluorescent dyes: anti-mouse B220-APC (B-cell surface marker) (Pharmingen, catalog number 01129A), anti-mouse Igb FITC (Southern Biotechnology Associates, catalog number 1830-02), and anti-human Igb PE (Pharmingen, catalog number 555679). Isotype-matched monoclonal controls were labeled with FITC, PE, and APC. Using a FACSCalibur flow cytometer (BD Immunocytometry systems) 10 000-20 000 cell events were acquired. The lymphocyte population to be analyzed was selected by side scatter and forward scatter. Analyses of the stained cells were performed using Cell Quest Software.
Protein extraction and Western blotting
Proteins from tissues and cell lines were purified in proteinase inhibitor buffer (1 mM potassium acetate, 1.5 mM magnesium acetate, 2 mM dithiothreitol (DTT), 10 mM Tris-HCl (pH 7.4), 100 mg of phenylmethylsulfonyl fluoride (PMSF)/ml, 2 mg of aprotinin/ml, 2 mg of pepstatin A/ml) by repeated pipetting. After clarification, the supernatants were separated and transferred using NuPage Bis-Tris gels system (Invitrogen). Signals were detected using monoclonal mouse anti-human Igb (Pharmingen) and polyclonal anti-L7a rabbit serum (Zimiecki, 1990; Ji et al, 2003) . Sheep anti-mouse IgG-HRP (Santa Cruz) and donkey anti-rabbit IgG-HRP (Amersham) were used as secondary antibodies.
Immunofluorescent microscopy
Polyclonal goat anti-hIgb antibodies (Santa Cruz Biotechnologies) and anti-hGH monoclonal antibodies (mAb 9) (Bennani-Baïti et al, 1998a, b) were used at a 1:1000 dilution. As secondary antibodies, donkey anti-goat Cy3 (Vector) and donkey anti-mouse Cy2 (Vector) were used at 1:200. Immunohistochemistry was performed on fresh frozen mouse spleen and pituitary sections. Defrosted slides were placed in buffered neutralized formalin for 5 min, transferred to distilled water, blocked with protein blocking agent (Immunotech) for 10 min and incubated overnight with the primary antibody at 41C. The next day the slides were washed and incubated for 30 min at 371C with the secondary antibodies. Finally, the slides were incubated for 10 s with 4 0 ,6-diamidino-2 phenylindole, dihydrochloride (DAPI), covered with mounting medium and observed under a fluorescence microscope.
Transgenic constructs and generation of transgenic mouse lines hGH/P1 wild-type and hGH/P1(DHSI) deletion lines have been previously reported (Su et al, 2000; Ho et al, 2002) (Table II) . À8.0Igb contains a 12 kb genomic fragment derived by EcoRI digestion of P1 6057 that includes 8.0 kb 5 0 to the hIgb gene and 975 bp 3 0 to the hIgb polyA addition site. À1.3Igb contains a 5.6 kb genomic fragment generated by BglII and EcoRI digestions with 1.3 kb of 5 0 -flanking sequences. À0.2Igb contains a 4.6 kb genomic fragment generated by BsiEI and EcoRI digestions that contains 200 bp of 5 0 -flanking region. Each construct was microinjected into fertilized mouse oocytes (C57BL/6 Â SJL) to generate the transgenic lines (Transgenic & Chimeric Mouse Core, University of Pennsylvania). Founders were identified by dot-blot analyses of tail DNA using a PCR-generated, 740 bp probe, corresponding to a region between exons 4 and 6 of the hIgb gene (Table I) . Transgenic lines used in the present study are listed in Table II . 
